{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T01:01:46Z","timestamp":1774486906949,"version":"3.50.1"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T00:00:00Z","timestamp":1765584000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004836","name":"Independent Research Fund Denmark","doi-asserted-by":"publisher","award":["9095-00029B"],"award-info":[{"award-number":["9095-00029B"]}],"id":[{"id":"10.13039\/501100004836","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011958","name":"Danmarks Frie Forskningsfond","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011958","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012774","name":"Innovation Fund Denmark","doi-asserted-by":"publisher","award":["0154-00037B"],"award-info":[{"award-number":["0154-00037B"]}],"id":[{"id":"10.13039\/100012774","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012774","name":"Innovation Fund Denmark","doi-asserted-by":"publisher","award":["9122-00084B"],"award-info":[{"award-number":["9122-00084B"]}],"id":[{"id":"10.13039\/100012774","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","esmoiotech.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Immuno-Oncology and Technology"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.iotech.2025.101581","type":"journal-article","created":{"date-parts":[[2025,12,19]],"date-time":"2025-12-19T17:18:37Z","timestamp":1766164717000},"page":"101581","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Safety and feasibility of blood-derived multiple antigen-specific endogenously derived T cells (MASE-T) for metastatic melanoma"],"prefix":"10.1016","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7217-2974","authenticated-orcid":false,"given":"T.J.","family":"Monberg","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.A.","family":"Tvingsholm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3934-464X","authenticated-orcid":false,"given":"M.","family":"Svensson-Frej","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Vestergaard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Ormh\u00f8j","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6201-1758","authenticated-orcid":false,"given":"J.W.","family":"Kjeldsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.H.","family":"Borch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5476-9937","authenticated-orcid":false,"given":"R.B.","family":"Holmstroem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Jayashankar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3382-0852","authenticated-orcid":false,"given":"J.S.","family":"Granh\u00f8j","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.R.","family":"Cordt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.K.","family":"Larsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1379-2647","authenticated-orcid":false,"given":"\u00d6.","family":"Met","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.R.","family":"Hadrup","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9451-6037","authenticated-orcid":false,"given":"I.M.","family":"Svane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"23","key":"10.1016\/j.iotech.2025.101581_bib2","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1056\/NEJMoa2210233","article-title":"Tumor-infiltrating lymphocyte therapy or ipilimumab in advanced melanoma","volume":"387","author":"Rohaan","year":"2022","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.iotech.2025.101581_bib3","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1038\/s41551-023-01023-3","article-title":"Isolation of tumour-reactive lymphocytes from peripheral blood via microfluidic immunomagnetic cell sorting","volume":"7","author":"Wang","year":"2023","journal-title":"Nat Biomed Eng"},{"issue":"12","key":"10.1016\/j.iotech.2025.101581_bib4","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1016\/j.ccell.2023.11.005","article-title":"Phenotypic signatures of circulating neoantigen-reactive CD8+ T cells in patients with metastatic cancers","volume":"41","author":"Yossef","year":"2023","journal-title":"Cancer Cell"},{"issue":"3","key":"10.1016\/j.iotech.2025.101581_bib5","first-page":"130","article-title":"Artificial antigen presenting cells: an off the shelf approach for generation of desirable T-cell populations for broad application of adoptive immunotherapy","volume":"04","author":"Hasan","year":"2015","journal-title":"Adv Genet Eng"},{"issue":"1","key":"10.1016\/j.iotech.2025.101581_bib6","first-page":"68","article-title":"The basics of artificial antigen presenting cells in T cell-based cancer immunotherapies","volume":"2","author":"Neal","year":"2017","journal-title":"J Immunol Res Ther"},{"key":"10.1016\/j.iotech.2025.101581_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2020.120584","article-title":"Biomaterials to enhance antigen-specific T cell expansion for cancer immunotherapy","volume":"268","author":"Isser","year":"2021","journal-title":"Biomaterials"},{"issue":"8","key":"10.1016\/j.iotech.2025.101581_bib8","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-006847","article-title":"TCR-engaging scaffolds selectively expand antigen-specific T-cells with a favorable phenotype for adoptive cell therapy","volume":"11","author":"Tvingsholm","year":"2023","journal-title":"J Immunother Cancer"},{"issue":"6","key":"10.1016\/j.iotech.2025.101581_bib9","first-page":"1200","article-title":"Comparison of the plasma volume-expanding effects of 6% dextran 70, 5% albumin, and 6% HES 130\/0.4 after hemorrhage in the guinea pig","volume":"67","author":"Dubniks","year":"2009","journal-title":"J Trauma"},{"key":"10.1016\/j.iotech.2025.101581_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbi.2019.103208","article-title":"The REDCap Consortium: building an international community of software platform partners","volume":"95","author":"Harris","year":"2019","journal-title":"J Biomed Inform"},{"issue":"2","key":"10.1016\/j.iotech.2025.101581_bib12","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","article-title":"Research Electronic Data Capture (REDCap) \u2013 a metadata-driven methodology and workflow process for providing translational research informatics support","volume":"42","author":"Harris","year":"2009","journal-title":"J Biomed Inform"},{"key":"10.1016\/j.iotech.2025.101581_bib13","series-title":"Ggplot2: Elegant Graphics for Data Analysis","first-page":"213","author":"Wickham","year":"2016"},{"key":"10.1016\/j.iotech.2025.101581_bib14","series-title":"GGsurvfit \u2013 Modeling Survival Data: Extending the Cox Model","first-page":"350","author":"Terry","year":"2000"},{"issue":"43","key":"10.1016\/j.iotech.2025.101581_bib15","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.21105\/joss.01686","article-title":"Welcome to the tidyverse","volume":"4","author":"Wickham","year":"2019","journal-title":"J Open Source Softw"},{"key":"10.1016\/j.iotech.2025.101581_bib16","author":"Iannone"},{"key":"10.1016\/j.iotech.2025.101581_bib17","series-title":"UMAP: Uniform Manifold Approximation and Projection for Dimension Reduction","author":"McInnes","year":"2018"},{"issue":"7","key":"10.1016\/j.iotech.2025.101581_bib18","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1002\/cyto.a.22625","article-title":"FlowSOM: using self-organizing maps for visualization and interpretation of cytometry data","volume":"87","author":"Van Gassen","year":"2015","journal-title":"Cytometry A"},{"key":"10.1016\/j.iotech.2025.101581_bib19","series-title":"FlowJoTM Software [software application] Version 10. Ashland: Becton, Dickson and Company","year":"2023"},{"issue":"8","key":"10.1016\/j.iotech.2025.101581_bib53","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.jcyt.2014.02.004","article-title":"Simplified protocol for clinical-grade tumor-infiltrating lymphocyte manufacturing with use of the Wave bioreactor","volume":"16","author":"Donia","year":"2014","journal-title":"Cytotherapy"},{"issue":"2","key":"10.1016\/j.iotech.2025.101581_bib20","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1038\/mt.2008.249","article-title":"Local IL-21 promotes the therapeutic activity of effector T cells by decreasing regulatory T cells within the tumor microenvironment","volume":"17","author":"Kim-Schulze","year":"2009","journal-title":"Mol Ther"},{"issue":"12","key":"10.1016\/j.iotech.2025.101581_bib21","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005755","volume":"10","author":"Chesney","year":"2022","journal-title":"J Immunother Cancer"},{"issue":"9","key":"10.1016\/j.iotech.2025.101581_bib22","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1111\/j.1537-2995.2008.01745.x","article-title":"Faint and prefaint reactions in whole-blood donors: an analysis of predonation measurements and their predictive value","volume":"48","author":"Wiltbank","year":"2008","journal-title":"Transfusion (Paris)"},{"issue":"7","key":"10.1016\/j.iotech.2025.101581_bib23","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1084\/jem.20050732","article-title":"Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells","volume":"202","author":"Gattinoni","year":"2005","journal-title":"J Exp Med"},{"issue":"10","key":"10.1016\/j.iotech.2025.101581_bib24","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1016\/j.molonc.2015.10.018","article-title":"Tumor-infiltrating lymphocytes for the treatment of metastatic cancer","volume":"9","author":"Geukes Foppen","year":"2015","journal-title":"Mol Oncol"},{"issue":"1","key":"10.1016\/j.iotech.2025.101581_bib25","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/s40425-018-0391-1","article-title":"Adoptive transfer of tumor-infiltrating lymphocytes in melanoma: a viable treatment option","volume":"6","author":"Rohaan","year":"2018","journal-title":"J Immunother Cancer"},{"issue":"2","key":"10.1016\/j.iotech.2025.101581_bib26","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.it.2004.12.003","article-title":"Sinks, suppressors and antigen presenters: how lymphodepletion enhances T cell-mediated tumor immunotherapy","volume":"26","author":"Klebanoff","year":"2015","journal-title":"Trends Immunol"},{"issue":"25","key":"10.1016\/j.iotech.2025.101581_bib27","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1056\/NEJM198812223192527","article-title":"Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report","volume":"319","author":"Rosenberg","year":"1988","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.iotech.2025.101581_bib28","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1093\/jnci\/86.15.1159","article-title":"Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2","volume":"86","author":"Rosenberg","year":"1994","journal-title":"J Natl Cancer Inst"},{"issue":"5","key":"10.1016\/j.iotech.2025.101581_bib29","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001743","article-title":"Comparison of non-myeloablative lymphodepleting preconditioning regimens in patients undergoing adoptive T cell therapy","volume":"9","author":"Nissani","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"20","key":"10.1016\/j.iotech.2025.101581_bib30","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1200\/JCO.2016.66.7220","article-title":"Randomized, prospective evaluation comparing intensity of lymphodepletion before adoptive transfer of tumor-infiltrating lymphocytes for patients with metastatic melanoma","volume":"34","author":"Goff","year":"2016","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.iotech.2025.101581_bib31","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-008640","article-title":"Biomarkers for response to TIL therapy: a comprehensive review","volume":"12","author":"Albarr\u00e1n Fern\u00e1ndez","year":"2024","journal-title":"J Immunother Cancer"},{"issue":"suppl 1","key":"10.1016\/j.iotech.2025.101581_bib32","first-page":"873","article-title":"Long-term efficacy and safety of lifileucel tumor-infiltrating lymphocyte (TIL) cell therapy in patients with advanced melanoma: a 4-year analysis of the C-144-01 study","volume":"11","author":"Medina","year":"2023","journal-title":"J Immunother Cancer"},{"issue":"11","key":"10.1016\/j.iotech.2025.101581_bib33","doi-asserted-by":"crossref","first-page":"3254","DOI":"10.7150\/jca.94109","article-title":"Revisiting temozolomide\u2019s role in solid tumors: old is gold?","volume":"15","author":"Matthaios","year":"2024","journal-title":"J Cancer"},{"issue":"15","key":"10.1016\/j.iotech.2025.101581_bib34","doi-asserted-by":"crossref","first-page":"3734","DOI":"10.1158\/1078-0432.CCR-15-1879","article-title":"Long-Lasting complete responses in patients with metastatic melanoma after adoptive cell therapy with tumor-infiltrating lymphocytes and an attenuated IL2 regimen","volume":"22","author":"Andersen","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.iotech.2025.101581_bib35","doi-asserted-by":"crossref","DOI":"10.1172\/JCI150535","article-title":"Neoantigen-reactive CD8+ T cells affect clinical outcome of adoptive cell therapy with tumor-infiltrating lymphocytes in melanoma","volume":"132","author":"Kristensen","year":"2022","journal-title":"J Clin Invest"},{"issue":"12","key":"10.1016\/j.iotech.2025.101581_bib36","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005678","article-title":"Dose-response correlation for CAR-T cells: a systematic review of clinical studies","volume":"10","author":"Rotte","year":"2022","journal-title":"J Immunother Cancer"},{"issue":"sup 1","key":"10.1016\/j.iotech.2025.101581_bib37","article-title":"8P Phenotypic characterization of infused tumor-infiltrating lymphocytes (TIL) correlates with response to adoptive cellular therapy (ACT) in patients with metastatic melanoma (MM)","volume":"16","author":"Stoltenborg Granh\u00f8j","year":"2022","journal-title":"Immunooncol Technol"},{"issue":"13","key":"10.1016\/j.iotech.2025.101581_bib38","doi-asserted-by":"crossref","first-page":"4550","DOI":"10.1158\/1078-0432.CCR-11-0116","article-title":"Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy","volume":"17","author":"Rosenberg","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.iotech.2025.101581_bib39","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1360281","article-title":"IMPROVE: a feature model to predict neoepitope immunogenicity through broad-scale validation of T-cell recognition","volume":"15","author":"Borch","year":"2024","journal-title":"Front Immunol"},{"issue":"4","key":"10.1016\/j.iotech.2025.101581_bib40","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.ccell.2020.07.013","article-title":"Identifying and targeting human tumor antigens for T cell-based immunotherapy of solid tumors","volume":"38","author":"Leko","year":"2020","journal-title":"Cancer Cell"},{"key":"10.1016\/j.iotech.2025.101581_bib41","article-title":"MART-1 TCR gene-modified peripheral blood T cells for the treatment of metastatic melanoma: a phase I\/IIa clinical trial","volume":"15","author":"Rohaan","year":"2022","journal-title":"Immunooncol Technol"},{"issue":"3","key":"10.1016\/j.iotech.2025.101581_bib42","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1182\/blood-2009-03-211714","article-title":"Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen","volume":"114","author":"Johnson","year":"2009","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.iotech.2025.101581_bib43","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1182\/blood-2013-03-490565","article-title":"Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma","volume":"122","author":"Linette","year":"2013","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.iotech.2025.101581_bib44","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1097\/CJI.0b013e3182829903","article-title":"Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy","volume":"36","author":"Morgan","year":"2014","journal-title":"J Immunother"},{"issue":"1","key":"10.1016\/j.iotech.2025.101581_bib45","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41392-022-01270-x","article-title":"Neoantigens: promising targets for cancer therapy","volume":"8","author":"Xie","year":"2023","journal-title":"Signal Transduct Target Ther"},{"issue":"16","key":"10.1016\/j.iotech.2025.101581_bib46","doi-asserted-by":"crossref","first-page":"3333","DOI":"10.1016\/j.cell.2023.06.020","article-title":"Targeting of multiple tumor-associated antigens by individual T cell receptors during successful cancer immunotherapy","volume":"186","author":"Dolton","year":"2023","journal-title":"Cell"},{"issue":"7","key":"10.1016\/j.iotech.2025.101581_bib47","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1158\/0008-5472.CAN-11-2614","article-title":"Dissection of T-cell antigen specificity in human melanoma","volume":"72","author":"Andersen","year":"2012","journal-title":"Cancer Res"},{"issue":"4","key":"10.1016\/j.iotech.2025.101581_bib48","doi-asserted-by":"crossref","first-page":"409","DOI":"10.4161\/onci.18851","article-title":"TIL therapy broadens the tumor-reactive CD8+ T cell compartment in melanoma patients","volume":"1","author":"Kvistborg","year":"2012","journal-title":"Oncoimmunology"},{"issue":"3","key":"10.1016\/j.iotech.2025.101581_bib49","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1038\/s41591-024-03418-4","article-title":"Personalized, autologous neoantigen-specific T cell therapy in metastatic melanoma: a phase 1 trial","volume":"31","author":"Borgers","year":"2025","journal-title":"Nat Med"},{"issue":"8","key":"10.1016\/j.iotech.2025.101581_bib50","doi-asserted-by":"crossref","DOI":"10.1172\/JCI177082","article-title":"T antigen-specific CD8+ T cells associate with PD-1 blockade response in virus-positive Merkel cell carcinoma","volume":"134","author":"Hansen","year":"2024","journal-title":"J Clin Invest"},{"issue":"8048","key":"10.1016\/j.iotech.2025.101581_bib51","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1038\/d41586-025-00217-w","article-title":"\u2018Dark proteins\u2019 hiding in our cells could hold clues to cancer and other diseases","volume":"637","author":"Callaway","year":"2025","journal-title":"Nature"},{"issue":"3 Pt 1","key":"10.1016\/j.iotech.2025.101581_bib52","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1158\/1078-0432.CCR-05-1544","article-title":"Tumor antigen expression in melanoma varies according to antigen and stage","volume":"12","author":"Barrow","year":"2006","journal-title":"Clin Cancer Res"}],"container-title":["Immuno-Oncology and Technology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590018825005416?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590018825005416?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T00:28:21Z","timestamp":1774484901000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2590018825005416"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":51,"alternative-id":["S2590018825005416"],"URL":"https:\/\/doi.org\/10.1016\/j.iotech.2025.101581","relation":{},"ISSN":["2590-0188"],"issn-type":[{"value":"2590-0188","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and feasibility of blood-derived multiple antigen-specific endogenously derived T cells (MASE-T) for metastatic melanoma","name":"articletitle","label":"Article Title"},{"value":"Immuno-Oncology and Technology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.iotech.2025.101581","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"101581"}}